Get the Stockscreener App
1.53
4.08%
0.06
Pre-market:
1.62
0.09
+5.88%
Pepgen Inc stock is traded at $1.53, with a volume of 451.67K.
It is up +4.08% in the last 24 hours and down -1.29% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$1.47
Open:
$1.49
24h Volume:
451.67K
Relative Volume:
0.34
Market Cap:
$105.83M
Revenue:
-
Net Income/Loss:
$-77.22M
P/E Ratio:
-0.8726
EPS:
-1.7533
Net Cash Flow:
$-77.27M
1W Performance:
+13.33%
1M Performance:
-1.29%
6M Performance:
-72.03%
1Y Performance:
+6.99%
1-Day Range:
$1.49
$1.55
1-Week Range:
$1.31
$1.55
52-Week Range:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.53 | 105.83M | 0 | -77.22M | -77.27M | -1.7533 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PEPG Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Continued R&D Progress - newsline.com
Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today - Stocktwits
PEPG Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Lack of RevenueEarnings Momentum Score - The League of Women Voters of Texas
PEPG Q1 2026 Earnings: Narrower Loss Per Share Beats Estimates as Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock HigherLow Estimate Range - newsline.com
PepGen Inc. (PEPG) Q1 2026 Earnings: Narrowed Loss Surprises Analysts, Shares Edge HigherReturn On Capital - newsline.com
PepGen Inc. (PEPG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Cautious OptimismGuidance Revision Trend - newsline.com
PepGen Inc. (PEPG) Rallies 4.23% as Biotech Stock Tests Key Resistance at $1.55Bollinger Expansion - newsline.com
PepGen showcases research advancements on DM1 at industry conference - Traders Union
PepGen attends ANN and AOMC Congress in Perth to engage neuromuscular research community - Traders Union
PepGen's cash reserves offer comfort for now, but rising cash burn and no revenue spark concerns. Investors are urged to remain cautious due to funding needs and dilution risk. - Moomoo
PepGen (PEPG) upgraded to buy: Here's what you should know - MSN
PepGen Inc. (PEPG): Stock Holds Steady at $1.50 as Key Resistance LoomsNAAIM Exposure - newsline.com
PepGen Inc. (PEPG) Nears Support as Stock Slips SlightlyEarnings Sentiment - The Legal Advocate
PepGen Inc. (PEPG) Slips to $1.5 as Stock Navigates Key Support ZoneBPI Bear Correction - The Legal Advocate
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Signals Progress in Neuromuscular PipelineCost Structure Review - The Legal Advocate
PepGen (NASDAQ: PEPG) CTO executes mandatory sell-to-cover RSU shares - Stock Titan
PepGen Inc. (PEPG) Slips 1.95% as Stock Tests Key Support LevelsSign of Weakness - Newser
PepGen launches outreach campaign with DM1 stakeholders in Canada - Traders Union
[EFFECT] PepGen Inc. SEC Filing - Stock Titan
PEPG Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Risk Report - newsline.com
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program - BioSpace
PepGen’s PGN-EDODM1 Shows Promising Safety and Efficacy in Myotonic Dystrophy Type 1 Clinical Trials – FREEDOM2 Study Update - Minichart
H.C. Wainwright reiterates PepGen stock rating on data outlook By Investing.com - Investing.com South Africa
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting - PharmiWeb.com
PepGen unveils new PGN-EDODM1 clinical data at IDMC-15 - Traders Union
PepGen Highlights DM1 Program Progress in Updated Presentation - TipRanks
H.C. Wainwright reiterates PepGen stock rating on data outlook - Investing.com
PepGen updates corporate presentation, highlights FREEDOM2 milestones and PGN-EDODM1 data - TradingView
PepGen (NASDAQ: PEPG) details DM1 trial data and cash runway outlook - Stock Titan
PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance UK
PepGen files to offer up to $400 mln in securities from time to time - marketscreener.com
PepGen Files To Offer Up To $400 Mln In Securities From Time To Time - TradingView
According to documents submitted to the SEC, biotechnology company PepGen Inc. has signed a new sales agreement, which will completely replace the company's previous sales arrangement. - Bitget
PepGen Files $400 Million Mixed Shelf - Moomoo
PepGen (NASDAQ: PEPG) ups capital flexibility with $400M shelf and $100M ATM - Stock Titan
PepGen Cuts Net Losses to 17.8 Million Dollars in First Quarter - HarianBasis.co
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - Insider Monkey
Why is PepGen stock sinking Tuesday? - MSN
Viking Global reports 3.48M shares in PepGen (NASDAQ: PEPG) - Stock Titan
[SCHEDULE 13G/A] PepGen Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Wedbush Maintains PepGen(PEPG.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside - TradingView
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating - marketscreener.com
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):